Physician profile
Brandon Morrow
NPI 1124486238
$1,469.49
in general payments reported to CMS, 2019-2025
21 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.59 · 2022: $460 · 2023: $372 · 2024: $329 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $928.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spine Wave, INC. | $298.45 | 2022-2024 | Proficient Posterior Cervical Spine System, Spinal Implant, Velocity Expandable Interbody System |
| Boston Scientific Corporation | $263.66 | 2022-2024 | |
| Medical Device Business Services, INC. | $137.01 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $121.13 | 2025 | |
| Ethicon US, LLC | $112.82 | 2022 | |
| Bioventus LLC | $79.79 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Medtronic, INC. | $73.58 | 2022-2024 | Intellis Adaptivestim |
| Si-Bone, INC. | $47.90 | 2022-2023 | |
| Globus Medical, INC. | $41.30 | 2022 | |
| Depuy Synthes Sales INC. | $38.42 | 2021 | |
| Lilly USA, LLC | $36.41 | 2023-2024 | Mounjaro |
| Abbvie INC. | $30.24 | 2022 | |
| Ossdsign USA Incorporated | $29.96 | 2025 | Ossdsign Catalyst |
| Organogenesis INC. | $28.32 | 2021 | |
| Atland Pharmaceuticals, LLC | $26.96 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.42 | 2024 | Andexxa |
| Azurity Pharmaceuticals, INC. | $20.60 | 2023 | Gliadel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.11 | 2022 | |
| Olympus America INC. | $14.85 | 2021 | |
| Endo USA, INC. | $14.39 | 2024 | Xiaflex |
| Pacira Pharmaceuticals Incorporated | $14.17 | 2025 | Zilretta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.